Abstract
This chapter focuses on torsades de pointes in the cancer population. We will discuss considerations in the measurement of QT intervals given the therapeutic impact this could have on chemotherapy selection and the pathophysiology of QT interval prolongation in this patient population. We then discuss in detail various cancer chemotherapy agents and their association with QT interval prolongation and torsades de pointes, highlighting potential mechanisms of their impact on cardiac repolarization, where known. Finally, we will describe the management of QT interval prolongation and torsades de pointes in patients with cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
